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Endothelial and Hematopoietic Cell Fate of Human
Embryonic Stem Cells Originates from Primitive
Endothelium with Hemangioblastic Properties
Establishment of pluripotent human embryonic stem
cell lines (hESC) (Thomson et al., 1998) provides a unique
opportunity to investigate the early developmental pro-
cesses of cell fate specification. Removal of hESCs from
culture conditions containing basic fibroblast growth
Lisheng Wang,1 Li Li,1 Farbod Shojaei,1,2
Krysta Levac,1 Chantal Cerdan,1
Pablo Menendez,1 Tanya Martin,1
Anne Rouleau,1 and Mickie Bhatia1,2,*
1Robarts Research Institute
factor (bFGF) (Xu et al., 2001) results in the aggregationKrembil Centre for Stem Cell Biology
of hESCs into clusters of cells termed human embryoidand Regenerative Medicine
bodies (hEB) capable of differentiation into all primary100 Perth Drive
germ layers (Schuldiner et al., 2000). However, it is un-London, Ontario N6A 5K8
clear whether the use of hESCs will recapitulate hemato-Canada
poietic and endothelial development as described in the2Department of Microbiology and Immunology
mouse or model the human embryo.The University of Western Ontario
Here, we identify a population of primitive endothelial-London, Ontario
like cells derived from human embryonic stem cellsCanada
(hESCs) that express PECAM-1, Flk-1, and VE-cadherin,
but not CD45 (CD45negPFV cells), that are uniquely re-
sponsible for endothelial and hematopoietic develop-Summary
ment, offering a model system to study mechanisms of
endothelial and hematopoietic lineage relationships inThe cellular organization and relationships among pre-
the human.cursors that initiate embryonic angiogenesis and he-
matopoiesis in the human have yet to be character-
Resultsized. Here, we identify a subpopulation of primitive
endothelial-like cells derived from human embryonic
Characterization of Human EB Development Priorstem cells (hESCs) that express PECAM-1, Flk-1, and
to Hematopoietic CommitmentVE-cadherin, but not CD45 (CD45negPFV cells), and that
Using conditions previously optimized to promote he-are uniquely responsible for endothelial and hematopoi-
matopoietic differentiation (Chadwick et al., 2003), weetic development. Molecular profiling of CD45negPFV
profiled hEB development to identify the onset of hema-cells is consistent with endothelial and hematopoietic
topoietic commitment by detection of cells expressingcompetency. Clonal isolation demonstrates that the
the panleukocyte marker CD45 and functional measure-CD45negPFV population includes bipotent cells with
ment of hematopoietic progenitor capacity as deter-endothelial and hematopoietic capacity. We suggest
mined by the colony-forming unit (CFU) assay (Eaves etthat human hematopoiesis and endothelial maturation
al., 1999).originate exclusively from a subset of embryonic endo-
Evidence of hematopoietic commitment was observedthelium that possesses hemangioblastic properties
on day 11 of hEB development in 18 independent experi-and offers a model system to study these lineage rela-
ments. CD45-expressing hematopoietic cells emergedtionships in the human.
only after 10 days of hEB development (Figures 1A and
1B), and functional hematopoietic progenitors were de-Introduction
tected at day 15 (Figure 1C). Individual hEBs were sec-
tioned and analyzed by immunohistochemistry, and no
Among vertebrates analyzed to date, initiation of embry-
CD45 expression was detectable until day 11 (Figure
onic hematopoiesis has indicated a close association
1D). The number of CD45 hematopoietic cells in-
with the major vasculature (Shalaby et al., 1997; Wood et creased beyond day 11 until large clusters of hematopoi-
al., 1997). In the human, similar studies of hematopoietic etic cells were detected at day 15 (Figure 1D), sug-
and endothelial development have been limited by diffi- gesting that hematopoietic precursors must emerge
culties associated with obtaining early human embryos, prior to the onset of hematopoietic cell fate at day 11
and lack of conditions capable of reproducing human of hEB development.
embryonic developmental processes in vitro. A few lines To examine the hematopoietic potential of cells com-
of evidence indicate that human hematopoietic cells first prising hEBs prior to the onset of hematopoietic com-
arise in the third week of human ontogeny within the mitment at day 11 of hEB development, cells were har-
developing blood vessels of the yolk sac and subse- vested at days 3, 7, and 10 from hEBs, verified to be
quently from independent origins within the wall of the devoid of hematopoietic cells (Figures 1E and 1F), and
embryonic aorta and vitelline artery (Oberlin et al., 2002; then cultured for 7 days in hematopoietic conducive
Tavian et al., 2001). However, the signals that govern conditions (Hem-Culture) (Bhatia et al., 1997). CD45
the complex relationship between hematopoietic and hematopoietic cells and hematopoietic progenitors
endothelial cell fate remain elusive, and further investi- (CFU) (Figures 1E and 1F) could be induced only be-
gation is dependent on the ability to identify human tween days 7 and 10 of hEB development, but not at
precursors with these developmental potentials. day 3 (Figure 1F). Based on these results, we define
a stage of hEB development where hematopoietically
competent precursors emerge within hEBs.*Correspondence: mbhatia@robarts.ca
Immunity
32
Figure 1. Characterization of Hematopoietic Cell Fate Emergence within Developing hEBs
(A) Single cells were prepared from hEBs that had been cultured in the presence of BMP-4 and cytokines, stained with fluorochrome-conjugated
monoclonal antibody CD45, and analyzed by flow cytometry at time points indicated. No CD45 cells were detected prior to 10 days of hEB
development as shown in this representative example.
(B) Summary of CD45 expression of cells comprising treated hEBs.
(C) Hematopoietic progenitors detected by the CFU assay were analyzed at various periods of hEB development as indicated.
(D) hEBs were sectioned and analyzed for CD45 (red) and alkaline phosphatase (blue) every day between day 10 and 15 of development.
CD45 (red) cells only emerged after 11 days (scale bar, 100 m).
(E) Single cells were prepared from hEBs at days 3, 7, and 10 prior to CD45 emergence and analyzed by flow cytometry (left). Single cells
were cultured in Hem-cultures for 7 days and then analyzed for CD45 (right) and CFU.
(F) CD45 expression and functional CFU capacity was detected only after Hem-culture from cells derived from days 7 and 10 hEBs (n  5).
Characterization of Candidate Hematopoietic in undifferentiated hESCs and cells comprising day 3
hEBs when hemogenic potential was absent, to hemato-Precursors Arising from hESCs
To identify cells contributing to hematopoiesis during poietically competent cells present at days 7 and 10 of
hEB development (Figures 1E and 1F). Of a series ofhEB development, we compared cell surface markers
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Figure 2. In Vivo Emergence of VE-Cadherin and PECAM-1-Expressing Cells within Developing hEBs
(A) Staining of VE-cadherin (red) and counterstaining with DAPI (blue) of hEBs. Positive VE-cadherin staining was observed at 7 and 10 days.
(B) Staining of PECAM-1 (red) and DAPI (blue) of sectioned hEBs. Cells with endothelial-like morphology (red) could be visualized at day 3
and at a higher frequency by days 7 and 10. (C) hEBs were harvested every day between days 10 and 15 and stained with CD45 (brown) and
PECAM-1 (blue). The majority of CD45 cells coexpressed PECAM-1 (purple, double-positive PECAM-1CD45 cells). By day 15, cells
expressing CD45 but absent for PECAM-1 were detected. Long scale bar, 100 m; short scale bar, 10 m.
markers compared and shown in Supplemental Table costained with PECAM-1 after day 11 to day 15 of hEB
development (Figure 2C) were consistent with the phe-S1 at http://www.immunity.com/cgi/content/full/21/1/
31/DC1, VE-cadherin and PECAM-1 were the only candi- notype of the first emerging hematopoietic cells in the
human embryo (Oberlin et al., 2002) and were neverdate markers that were absent from hESCs but were
upregulated prior to hematopoietic emergence between observed in hEBs independent of adjacent PECAM-1
cells (Figure 2C). We suggest that a subpopulation ofdays 3 and 10 of hEB development.
VE-cadherin-expressing cells were observed in dis- VE-cadherin and PECAM-1-expressing cells within
hEBs is associated with subsequent hematopoieticcrete clusters in days 7 and 10 hEBs but were not de-
tected at day 3 (Figure 2A), whereas PECAM-1, a marker commitment.
associated with cells capable of early hematopoietic
potential in the human embryo (Oberlin et al., 2002), was Isolation of Hematopoietic Precursors
from Human EBsfirst detected at day 3 by immunostaining (Figure 2B)
and significantly increased at day 7 through day 10. At VE-cadherin/PECAM-1 cells were directly isolated
from day 10 hEBs by FACS and compared to all re-day 10, hEBs containing PECAM-1 cells were devoid
of committed hematopoietic cells (CD45), whereas, maining cells within the hEB (remaining day 10 hEB
cells). Single viable cells excluding 7-AAD (gated R1)by day 11, CD45 cells emerged and were exclusively
found adjacent to PECAM-1 cells. Most CD45 cells were isolated based on the absence or presence of
Immunity
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Figure 3. De Novo-Isolated Subsets Derived from Day 10 hEBs Possess Endothelial Properties
Subsets were isolated from day 10 hEBs (excluding 7AAD cells) and reanalyzed ([A]–[C]; n  8). In contrast to the R1  R2 sorted subset
that was negative for CD34 and Flk-1 cell surface expression (D), up to 97% of R1 and R3 sorted cells (E) expressed CD34 (92.11%  4.84%;
n  6) and Flk-1 (84.34%  13.14%); however, all cells within the R1 and R3 sorted population expressing PECAM-1 expressed Flk-1 and
vice versa. (F) Determined by immunohistochemistry, R1  R2 isolated cells possessed metabolic function for Dil-Ac-LDL uptake (red) and
coexpressed the endothelial marker VE-cadherin (green) but lacked expression of CD45, vWF, and eNOS. (G) Remaining cells within the day
10 hEB gated R1 and R3 were negative for markers indicated. Staining of cells with vWF and eNOS is overlayed onto Hoffman images. Scale
bar, 10 m.
PECAM-1 (R2 and R3, respectively; Figure 3A). Upon fraction was ambiguous but could not be formally ex-
cluded based on quadrant analysis using flow cytometryreanalysis, the purity of viable R1  R2 gated cells was
99.1%  0.9%, and R1  R3 gated cells was 91.9%  (Figure 3E, right panel). However, based on the proximity
of cells with either a PECAM-1Flk-1 or PECAM-1.5% for PECAM-1 (Figures 3B and 3C). In contrast to
R1 and R2 sorted cells (Figure 3D), an average of 1Flk-1 phenotype to the major PECAM-1Flk-1
subset, these few events most likely represent cells with92.1%  4.8% of R1  R3 gated cells coexpressed
CD34 (Figure 3E) and 84.3% 13.1% coexpressed Flk-1 slightly less detectable PECAM-1 or Flk-1 fluorescence
that upon reanalysis fall just outside the PECAM-1Flk-(Figure 3E). R1  R2 sorted remaining day 10 hEB cells
were almost exclusively devoid of either PECAM or Flk-1 1-defined quadrant (Figure 3E, right panel), thereby
precluding any meaningful separation for subsequentexpression (Figure 3D, right panel). The R1 and R3
sorted fraction contained a low frequency of Flk-1 cells functional analysis. Direct isolation of CD45, Flk-1,
or double positive Flk-1/PECAM-1 cells from day 10(Figure 3E, M1). However, these cells were also devoid of
PECAM-1 expression (Figure 3E, right panel), indicating hEB demonstrated that VE-cadherin segregated with
either of these populations, indicating that any of thesethat they most likely originate from the abundant
PECAM-1Flk-1 cells comprising day 10 hEBs during sorting strategies isolate a functionally and phenotypi-
cally similar population with a CD45, VE-cadherin/purification of the PECAM-1Flk-1 cells. The pres-
ence of rare cells with either a PECAM-1Flk-1 or PECAM-1/Flk-1 phenotype (Supplemental Figure S1
on Immunity’s website).PECAM-1Flk-1 phenotype within the R1R3 sorted
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Since some markers are shared between endothelial CFU capacity. A low frequency of CFU was obtained
from the CD45CD34 population (1 in 1069), whereasand hematopoietic cells, definitive evidence to distin-
guish these lineages requires a combination of pheno- CD45CD34 cells were highly enriched (1 in 50) for
CFU (Figure 4Q). Thus, hESC-derived hematopoietictypic and functional indices (Ema et al., 2003; Nishikawa
et al., 1998). Accordingly, we have used the absence of progenitor capacity was enriched in the CD45CD34
subfraction. Our results indicate that CD45negPFV cellsCD45 and hematopoietic progenitor function, in addition
to the presence of PECAM-1, CD34, Flk-1, VE-cadherin, represent a unique subpopulation of endothelial-like
cells that exclusively account for hematopoietic devel-uptake of LDL, wWF, and eNOS, as our criteria for defin-
ing endothelial cells derived from hEBs (Rafii and Lyden, opment from hESCs, giving rise to CD45CD34 cells
with multilineage progenitor capacity.2003). To avoid false negatives or false positives, human
umbilical vein endothelial cells (HUVEC) and mouse em-
bryonic fibroblast cells (MEF) served as respective con- Endothelial-like CD45negPFV Precursors Isolated
trols (Figure 5). from hEBs Are Capable of Endothelial Maturation
Selected subsets shown in Figure 3D (R1  R2) and CD45negPFV cells and remaining day 10 hEB cells were
Figure 3E (R1  R3) were analyzed by immunohisto- cultured for 7 days in conditions conducive to endothelial
chemistry after de novo isolation (Figure 3G). The subset maturation (endo-culture) containing pituitary extracts and
of CD45 cells from day 10 hEBs that were isolated VEGF (Murohara et al., 2000). After 7 days in endo-culture
based on PECAM-1 or Flk-1 all demonstrated the func- conditions, functional uptake of Dil-Ac-LDL and expres-
tional ability to uptake Dil-Ac-LDL and also expressed sion of PECAM-1, VE-cadherin, CD45, vWF, eNOS, and
PECAM-1 and VE-cadherin (Figure 3F). Cells capable of hematopoietic progenitor capacity were examined.
LDL uptake were confirmed to be nonhematopoietic by Endo-cultured CD45negPFV cells became attached and
the absence of CD45 expression (Figure 3F). However, spindle shaped (Figure 5), strongly expressed PECAM-1
more mature features of functional endothelium (Rafii and VE-cadherin, and possessed higher LDL uptake ca-
and Lyden, 2003), such as expression of vWF and eNOS, pacity (Figure 5), as compared to de novo-isolated cells
were not detected, suggesting this subset does not con- (Figure 3F). In contrast to properties of de novo-isolated
tain fully mature endothelial cells (Figure 3F). In contrast, CD45negPFV cells (Figure 3F), endo-cultured CD45negPFV
the remaining day 10 hEB cells (R1 and R2) did not cells expressed vWF and eNOS (Figure 5) indicative of
possess any of these endothelial characteristics (Figure endothelial maturation. No CD45 expression could be
3G). Based on these multiple parameter analyses, we detected after culture under these conditions (Figure 5),
define this unique subset of cells at day 10 of hEB devel- consistent with the complete absence of hematopoietic
opment that lack CD45 expression; express PECAM-1, CFU capacity (data not shown). Remaining day 10 hEBs
Flk-1, and VE-cadherin; and possess phenotypic and were negative for all endothelial markers tested after 7
functional endothelial-like properties, as CD45negPFV days of endo-culture (Figure 5). Our combined results
cells. indicate that CD45negPFV cells represent a unique popu-
lation of endothelial-like cells with hemogenic properties
and retain the functional ability to differentiate into ma-Hematopoietic Cells Are Derived from Endothelial-
ture endothelium.like CD45negPFV Precursors Isolated from hEBs
CD45negPFV and remaining day 10 hEB cells were cul-
tured in Hem-culture conditions for 7 days and then CD45negPFV Cells Possess a Distinct Molecular
Profile Consistent with Both Hematopoieticassessed for hematopoietic commitment by CD45 ex-
pression and the ability to give rise to hematopoietic and Endothelial Potential
The unique ability of CD45negPFV cells to differentiateprogenitors (CFU) compared to unsorted cells derived
from day 10 hEBs. Total number of cells from into both hematopoietic and endothelial cells (Figures 4
and 5) prompted us to investigate their gene expressionCD45negPFV cultures increased (1.36-  0.47-fold) over
7 days and appeared as single round cells (Figure 4A), signature. Classification of differentially regulated genes
in CD45negPFV versus hESCs and day 10 hEBs dividedwhere up to 98.5% of these cells were CD45 (Figure
4A), with 8.3%  0.7% coexpressing CD34 (Figure 4A). them into three groups, including genes representing
endothelial (Figure 6A), hemogenic (Figure 6B), andIn contrast to CD45negPFV cells, the remaining day 10
hEB cells or unsorted cells demonstrated a decrease in hemogenic-endothelial (Figure 6C) potentials. See Sup-
plemental Table S2 on Immunity’s website for the com-cell number by 5.48- 1.87-fold after 7 days in hemato-
poietic culture conditions. Overall, the number of CD45 plete differential gene expression profile of upregulated
genes in CD45negPFV cells. Endothelial factors vWFhematopoietic cells generated from CD45negPFV cells
was 28.7- 8.2- and 146.1- 89.5-fold higher than from (Guo et al., 2003a) and eNOS (Venugopal et al., 2002)
transcripts were highly expressed, consistent with theunsorted or remaining day 10 hEB cells, respectively
(Figures 4B and 4C). In addition, cultured CD45negPFV upregulation of protein expression upon endo-culture
(Figure 5). In addition, expression of several adhesioncells generated a 124-fold higher number of colonies
compared to remaining day 10 hEB cells or unsorted molecules, such as CD34, VE-cadherin, PECAM-1, En-
dothelin, LFA-3, and E-Selectin, was also consistentcells (Figure 4D). As shown, morphology and phenotype
of CFUs derived from CD45negPFV cells were similar to with the cellular characteristics of embryonic endothe-
lium (Neumuller and Menzel, 1997). Consistent with theadult hematopoietic sources (Figures 4E–4M).
CD45CD34 and remaining CD45CD34 sub- de novo endothelial-like properties of CD45negPFV cells,
several signal transduction genes known to play a rolepopulations were isolated from 7 day Hem-cultures of
CD45negPFV cells (Figures 4N and 4O) and assayed for in endothelium, including TIE-2, Neuropilin, EDG-1, and
Immunity
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Figure 4. CD45negPFV Cells Derived from Day 10 hEBs Possess Hemogenic Potential
(A) Total cell numbers after Hem-culture increased in cultures seeded with CD45negPFV cells (1.36-  0.47-fold increase; n  6), and the
majority of cells appeared as single, round cells (scale bar, 50 m). CD45negPFV subset gave rise to up to 98.5% of CD45 hematopoietic
cells, and 8.3%  0.7% of those CD45 cells were also CD34. In contrast, remaining day 10 hEB subset (appeared spindle shaped)
demonstrated no growth in Hem-culture, and total cell numbers decreased significantly (5.48-  1.87-fold decrease; n  6). Total CD45
cells (B) or CD45CD34 cells (C) and CFUs (D) derived from unsorted or sorted CD45negPFV and remaining day 10 hEB cells. CD45negPFV
subset showed 124.20 (66.70; n  3) -fold higher numbers of CFU than remaining day 10 hEB subset. Representative colonies from hEB-
derived CD45 cells are depicted, including macrophage (E), granulocyte (F), erythroid (G), and multipotent (H) colonies. Cells from the
macrophage, granulocyte, or erythroid colonies, identified by light microscopy, contained monocytes (I), granulocytic (J), or erythroid cells
(K), by Wright-Giemsa staining. The granulocytic cells were characterized by segmented nuclei and pink or dark blue cytoplasmic granules
([J] and insets). Cells comprising myeloid colonies expressed CD45, myelomonocytic markers CD33 and CD13, and lacked erythroid
glycophorin A marker (L). Erythroid colonies contained mature enucleated erythrocytes ([K], arrow), expressed glycophorin A, and CD45 (M)
(scale bar, 100 m in [E]–[H]; scale bar, 10 m in [I]–[K]). CD45 cells were separated into CD45CD34 and CD45CD34 subfractions
(N and O), and CFU efficiency of CD45CD34 and CD45CD34 cells was compared (P).
TEK (Breier, 2000), were highly expressed. As would be prominent (data not shown); however, CD45negPFV cells
expressed transcription factors that would be requiredexpected in cells with endothelial-like characteristics,
hematopoietic cytokine signaling pathways were not for hemogenic potential and priming of the hematopoi-
Hemogenic Endothelium from Human ES Cells
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Figure 5. Human EB-Derived CD45negPFV Are Capable of Endothelial Maturation
Using primary HUVEC cells (column 1) as a positive control and mouse embryonic fibroblasts (MEF, column 2) as a negative control, CD45negPFV
(column 3) and remaining day 10 hEB cells (column 4) were cultured in endo-culture and analyzed for endothelial cell fate. For Dil-Ac-LDL
uptake (red), cells were incubated with red-fluorescent Dil-Ac-LDL prior to immunocytochemical analysis, such as PECAM-1, VE-cadherin
(VE), vWF, and eNOS markers, shown in green. vWF and eNOS staining was overlaid onto Hoffman images. Cultured remaining day 10 hEB
cells showed little Dil-Ac-LDL uptake and were negative for endothelial markers shown (column 4). No positive stain was observed for CD45
(n  4). Scale bar, 10 m. Negative staining of MEFs was overlaid onto Hoffman images in insets.
etic cell fate programs. These hemogenic factors included of human CD45negPFV is consistent with the dual hemo-
genic and endothelial potential of these cells.FLI-1, MPL, Lymphocytic leukemia derived sequence-1
(LLD-1), MYB, and ERG (Orkin and Zon, 1997). Genes
associated with primitive cells with both endothelial and The CD45negPFV Subpopulation Contains Single Cells
with Both Hematopoietic and Endothelial Capacityhemogenic potential were also highly expressed in
CD45negPFV cells, supportive of human hemangioblast Single CD45negPFV cells isolated from day 10 hEBs were
deposited into individual wells of a 96-well plate andfunction of CD45negPFV cells. These include FLT-1 (Ca-
sella et al., 2003), FLK-1 (Ema et al., 2003), TAL-1 (Ema inspected daily. A total of 1169 individual wells targeted
for single CD45negPFV cell deposition were visually in-et al., 2003), FLT-4 (Fielder et al., 1997), FOG-1 (Katz et
al., 2002, 2003), RUNX-1 (Bailey and Fleming, 2003), and spected at 2 hr and again at 16 hr post-clonal isolation.
This inspection was performed by two independent ob-HEX (Guo et al., 2003b). Therefore, the molecular profile
Immunity
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lial cell fate, respectively. To establish appropriate in
situ controls for CD45 and VE-cadherin staining, primary
HUVECs, adult hematopoietic mononuclear cells (MNC),
and CD45-expressing hematopoietic cells derived from
hESC cells were similarly deposited (Figure 7A), stained,
and compared to isotype controls (Figure 7B). Only en-
dothelial HUVEC cells were positive for VE-cadherin
(red) and negative for CD45 (green), whereas both adult
and hESC-derived hematopoietic cells were positive for
CD45 and negative for VE-cadherin (Figure 7B). This
established our comparative criteria for identifying
clones with hematopoietic, endothelial, or bipotent en-
dothelial and hematopoietic potential.
Based on these clonal culture conditions (50:50 vol
Hem:Endo Culture), a total of 1152 individual wells were
analyzed using established criteria defined by positive
and negative in situ controls (Figures 7A and 7B). Isola-
tion strategy of the CD45negPFV cells and reanalysis of sort
purity (98.26%  0.51%) for these clonal experiments is
shown in Supplemental Figure S2 on Immunity’s website.
Of the 1152 wells, 37 wells (3.2%) demonstrated clonal
outgrowth, consistent with previous studies that have
reported the difficulty of sustaining single cells differen-
tiated from mammalian ES parents in culture (Choi et al.,
1998; Lumelsky et al., 2001). The progeny of CD45negPFV
clones detectable after cultures were subsequently ex-
amined for hematopoietic and endothelial cell differenti-
ation by in situ analysis of individual wells.
Consistent with previous results (Figures 4 and 5),
progeny of CD45negPFV clones were either exclusively
hematopoietic (Figure 7C) or endothelial (Figure 7D).
However, in addition to these CD45negPFV clones with
unilineage differentiation capacity (Figures 7C and 7D),
quantitative analysis demonstrated that 0.18% of the
total wells seeded with single CD45negPFV clones were
capable of giving rise to both endothelial and hemato-
poietic progeny (Figure 7E). These wells were interpre-
ted to be the result of differentiation of bipotent
CD45negPFV clones, suggesting that a proportion of
CD45negPFV cells possess both endothelial and hemato-
poietic potential. Based on the clonal analysis of
CD45negPFV cells derived from hESCs, we suggest that
the CD45negPFV subset contains cells with human hem-
Figure 6. Molecular Profiling of CD45negPFV Cells angioblastic properties.
Total RNA of hESC cells, CD45negPFV, and remaining day 10 hEB
cells were extracted, and aRNA was generated to hybridize human
DiscussionHG-U133AB Affymetrix chips. Expression level of CD45negPFV and
remaining cells within day 10 hEBs was calculated relative to hESC
cells. Differentially regulated genes were defined as those being Invertebrates possess a vascular system that is open
upregulated more than 2-fold in CD45negPFV versus remaining day to the interstitial space and, therefore, is permissive
10 hEB cells and being statistically significant (p 0.05) using three to the entry of developing hematopoietic cells into the
biological replicates. Markers representing endothelial potential of circulation. In the mammal, a more efficient closed circu-
CD45negPFV (A), defining hemogenic potential (B), and describing
latory system has evolved, necessitating the formationboth hemogenic and endothelial potentials (C) are shown.
of endothelial vasculature that itself gives rise to hema-
topoietic cells, thereby allowing incorporation of blood
cells into this closed system. Consistent with this para-servations blinded to the others’ results. Both observers
demonstrated 100% concordance of wells that con- digm, our study identifies CD45negPFV progenitors
emerging during differentiation of hESCs and providestained more than one cell, at either time point after depo-
sition, and these wells were then excluded from subse- evidence that human hematopoietic cells arise from en-
dothelial-like precursors that can give rise to either he-quent analysis.
After 14 days in wells confirmed to contain clonal matopoietic cells or committed endothelium. The ability
to isolate and differentiate these precursors into eitherstarts, individual cells were identified by DAPI staining
that resulted from single CD45negPFV cell proliferation hematopoietic or endothelial lineages provides the foun-
dation to investigate the cellular and molecular eventsand were analyzed in situ for expression of CD45 and
VE-cadherin, representing hematopoietic and endothe- leading to the development of these precursors in the
Hemogenic Endothelium from Human ES Cells
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Figure 7. Clonal Analysis of the Hematopoietic and Endothelial Developmental Potential of CD45negPFV Cells
The cells resulting from single CD45negPFV cell proliferation in each well were analyzed in situ for expression of CD45 (hematopoietic cell fate)
and VE-cadherin (endothelial cell fate). (A) HUVEC cells, adult hematopoietic mononuclear cells (MNC), and CD45-expressing hematopoietic
cells derived from hESC cells (hESCCD45) as positive controls and compared to (B) isotype-staining controls (VE-cadherin, red; CD45,
green; DAPI nucleus staining, blue). A schematic illustration representing the location of CD45negPFV progeny within individual wells containing
(C) only hematopoietic progeny, (D) only endothelial progeny, or (E) individual wells containing cells of both hematopoietic and endothelial
progeny originally seeded with only one CD45negPFV cell. Scale bar, 10 m. Dispersed location of cells is due to the physical manipulations
(movement) of plates necessary at 2 and 16 hr, at subsequent daily inspections, and at addition to culture media. (F) Working model of the
cellular development toward endothelial and hematopoietic cell fate during hESC differentiation.
human. Furthermore, our report demonstrates that pre- progresses via discrete cell types that become more
restricted, thereby describing a hierarchical organiza-cursors of a specific tissue lineage can be prospectively
isolated from hEBs, indicating the hESC differentiation tion of cell fate commitment from hESCs. We propose
Immunity
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was performed according to the methods described (Boldicke eta working model that outlines our current understanding
al., 2001). Live cells identified by 7-AAD exclusion (Immunotech)of hematopoietic cell fate specification from hESCs (Fig-
were analyzed for surface marker expression using a FACSCaliburure 7F).
and Cell Quest software (BD).
Functional hemogenic capacity emerged between 7
and 10 days of hEB development. Based on the literature Immunohistochemistry of hEB Sections
and available markers for human cells, our study used Cultured hEBs were snap frozen and cryosectioned as described
the presence of PECAM-1, CD34, Flk-1, VE-cadherin, (Chadwick et al., 2003). For each staining, three sections per speci-
men at an interval of 30 serial sections were used. The mAb useduptake of LDL, and absence of CD45 or hematopoietic
in this study were mouse anti-human VE-cadherin, PECAM-1, CD45,progenitor function as the multiparameter criteria for
and mouse IgG1 isotype (BD) at 5 g/mL. Sections were incubateddefining endothelial-like cells (Rafii and Lyden, 2003). A
with the above mAbs for 2h, followed by Alex Flour 568 goat anti-
unique subset of CD45neg hEB cells lacking hematopoi- mouse IgG (Molecular Probes) for 30 min, and then counterstained
etic progenitor capacity but possessing endothelial-like with DAPI. For PECAM-1/CD45 double staining, sections were first
properties could be isolated from hEBs prior to the emer- stained with anti-PECAM-1 mAb by Vector ABC-AP kit and visual-
ized with Vector Blue. Subsequently, the sections were incubatedgence of hematopoietic cell fate. Despite functional Dil-
with anti-CD45 mAb for 30 min by Vector MOM kit and visualizedAc-LDL uptake, expression of Flk-1, VE-cadherin, and
with Vector ABC-peroxidase using AEC. CD45/AP double stainingCD34, these endothelial-like cells lacked more mature
was performed as described (Chadwick et al., 2003).
endothelial properties, such as eNOS or vWF factor ex-
pression (Rafii, 2000). Hemogenic capacity of hEBs was
Preparation of Isolated Subpopulations and Single
unique to endothelial-like CD45negPFV cells, and little CD45negPFV Cells
hematopoiesis was detected in remaining hEB cells, CD45negPFV and remaining day10 hEB cells were dissociated from
suggesting that the CD45negPFV subset exclusively con- day 10 hEB and stained with Flk1 followed by PECAM-1-FITC (Phar-
Mingen), CD45-APC (BD), and 7-AAD. Cell subpopulations or singletained hematopoietic developmental potential (Figure
cells were sorted on a FACSVantage SE (BD).7F). When stimulated with VEGF and pituitary hormones,
CD45negPFV cells were able to produce mature endothe-
Culture of hEB-Derived CD45negPFV and Remaininglial cells that continued to express endothelial markers,
Day 10 hEB Cellsand upregulated eNOS and wWF expression (Figure 7F).
Isolated CD45negPFV and remaining day 10 hEB subpopulations were
Taken together, our study reveals that the CD45negPFV seeded on fibronectin-coated plates (5 104 cells/cm2) and cultured
population is responsible for both hematopoietic and for 7 days in conditions previously designed and shown to sustain
human hematopoietic stem cells (Bhatia et al., 1997) or in Medium-endothelial cell fate and contains CD45negPFV clones
199 supplemented with 20% FBS, 50 g/mL of bovine pituitarywith bipotent lineage potential, thereby providing a
extract as an endothelial cell growth supplement (Invitrogen), 10model system to generate functional human hemangi-
IU/mL of heparin (Leo Pharna Inc.), and 5 ng/mL of hVEGF (R & Doblasts (Traver and Zon, 2002).
Systems). Medium was changed at days 2, 4, and 6.
The use of surrogate cell surface markers to discrimi-
nate murine hematopoietic precursors during embryo Uptake of Acetylated LDL and In Situ Immunocytochemical
development or differentiation of mouse ES cells has Staining for PECAM-1, VE-Cadherin, CD45, vWF, and eNOS
been reported. However, our current study indicates HUVEC (positive control), mouse embryonic fibroblasts (MEF, nega-
tive control), de novo isolated or cultured CD45negPFV, and remainingthat many of these markers are expressed on undifferen-
day 10 hEB cells were incubated with 10 g/mL of Dil-Ac-LDLtiated hESCs and were not regulated upon differentia-
(Molecular Probes) at 37	C for 4 hr. After fixation, cells were stainedtion of hEBs, thereby excluding their use for identifica-
for 30 min with 5 g/mL of primary anti-PECAM-1, VE-cadherin,
tion of hESC-derived hematopoietic precursors. These CD45, mouse IgG1 isotype (BD), vWF (DAKO), or eNOS mAb (BD),
results illustrate differences in cellular development of followed by fluorescein-conjugated goat anti-mouse IgG (IMMUNO-
mouse and human ESCs toward the hematopoietic lin- TECH). The cells resulting from single CD45negPFV cell proliferation
in each well were fixed and stained with anti-CD45 as describedeage and suggest that uncovering the mechanisms of
above and then double stained with VE-cadherin mAb by Vectorshuman hematopoietic cell fate decisions will depend on
MOM kit, visualized with Vectors Texas Red-Streptavidin, and coun-human systems. Due to the difficulty in studying these
terstained with DAPI. All immunostaining specimens were coded
complex processes during the early stages of human and analyzed blindly with computer-assisted image analysis capa-
embryo development, differentiation of hESCs provides bilities (Image Pro-Plus).
an ideal alternative model.
Molecular Profiling
Experimental Procedures Total RNA was extracted using Qiagen RNAeasy kit (Qiagen) and
was amplified using Message Amp aRNA kit (Ambion) (Raghavachari
hESC Cell Culture and hEB Formation et al., 2002). Fifteen micrograms of fragmented antisense RNA
Maintenance of hESC lines H9 or H1 (Thomson et al., 1998), forma- (aRNA) was used for hybridizing human HG-U133AB arrays (Affymet-
tion of hEB, and preparation of single cells from hESC, hEB, and rix) at the London Regional Genomic Center (Ontario, Canada). Gen-
hematopoietic colonies were performed as previously described eSpring 6.0 was used for data analysis. Genes that were flag passed
(Chadwick et al., 2003; Xu et al., 2001). in at least one of the populations and significantly (p 0.05, different
by 2-fold) upregulated in CD45negPFV, in comparison to both hESC
and remaining day10 hEB cells, are shown.Analysis of Cell Surface Markers by Flow Cytometry
Single-cell suspensions (2–5  105 cells/mL) were stained with fluo-
rochrome-conjugated monoclonal antibodies (mAb), including CD45, Acknowledgments
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